Category Archives: Clinical Cardiology

Munich, Germany (31 August 2020) Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced one-year results of four sub-analyses from the European and global ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) programme, a non-interventional safety study evaluating edoxaban treatment in routine clinical practice in > 26,000 patients around the world with atrial fibrillation (AF).1,2,3,4 New 12-month data from the European and global ETNA-AF registries showed rates of bleeding and intracranial haemorrhage (ICH) were considered low by the authors assessment in frail and ageing patients in routine clinical care.1,2,3 Findings, which are part of the largest prospective, non-interventional study programme investigating a single direct oral anticoagulant (DOAC) in patients with non-valvular atrial fibrillation (NVAF) to date, are available virtually at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, taking place 29 August 01 September. In vulnerable populations such as the ageing, frail and those with renal impairment, anticoagulation for stroke prevention is often not prescribed due to the risk of bleeding, despite these patients being among those most at risk for ischaemic events like stroke.5 However, outcomes from ETNA-AF reinforce the effectiveness and safety of edoxaban in these populations.1,2 Ageing and frail patients have been underrepresented in certain AF stroke prevention trials, leaving a lack of evidence to support routine DOAC use in these patients. However, these new data should provide clinicians with some confidence of edoxabans efficacy and safety profile to reduce the risk of stroke for the ageing and frail AF populations, Dr Ameet Bakhai, Consultant Cardiologist & Cardiovascular R&D Director Royal Free London NHS Trust, UK Continue reading →

Sophia Antipolis, France August 31, 2020:A survey of nurses caring for children with heart problems has revealed that more than half are emotionally exhausted. The analysis, presented at ESC Congress 2020, also found that good working environments were linked with less burnout.1 Nurses wellbeing is central to ensuring the best outcomes for patients, said study author Dr. Annamaria Bagnasco of the University of Genoa, Italy Continue reading →

More than half of patients who experience out-of-hospital cardiac arrest (OHCA) visit their general practitioner within the 2 weeks prior to their event, according to new Danish registry data. Continue reading →

After TAVR, patients who do not have an indication for oral anticoagulation fare better with aspirin alone than with dual antiplatelet therapy, the POPular TAVI trial shows. Patients treated with aspirin monotherapy rather than aspirin plus 3 months of clopidogrel had much lower rates of bleeding without an increase in thromboembolic events, Jorn Brouwer, MD (St. Continue reading →

SAN FRANCISCO and SUZHOU, China, Aug. 30, 2020 /PRNewswire/ --Innovent Biologics, Inc Continue reading →

MITRE on Tuesday announced two new collaborations based around its mCODE data standard. One will bring voice recognition capabilities to the oncology dataset, and another will see it working with the Mayo Clinic to build out and automate that and other data platforms to enable better care for cardiology, COVID-19 and more Continue reading →

August 29, 2020 09:30 ET | Source: MyoKardia, Inc. EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet Presentation Expands on Positive Topline Results Showing Early, Sustained Reductions in Biomarkers of Cardiac Wall Stress and Myocardial Injury Mavacamten Demonstrated Broad Treatment Effect, with Consistent Benefit Across Primary and Secondary Endpoints Among All Prespecified Patient Subgroups MyoKardia to Host a Virtual Analyst and Investor Event to Review Data on Monday, August 31 at 8:00 a.m. EDT BRISBANE, Calif., Aug Continue reading →

As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indicationbut there were some signs of hope. Now, a new Entresto study is again showing promise in that patient population, but it's not a resounding win. Continue reading →

In recent years, the advancement of wearable technology and health/performance-related heart monitoring systems have provided clinicians an opportunity to bridge the gap between consumers and proactive care for atrial fibrillation risk. Namely, a common yet under-diagnosed condition like atrial fibrillation (AF)linked to greater major adverse cardiovascular events (MACE) and even dementiacould be better addressed with the bevy of data coming available from consumer technology. In a virtual presentation at the European Society of Cardiology (ESC) 2020 Congress this weekend, Emma Svennberg, MD, PhD, of the Karolinska University Hospital in Sweden, discussed the progress made in this venture and how it pertains to a greater questionand the name of her session: Will digital health finally solve the problem of asymptomatic atrial fibrillation screening Continue reading →

The Centers for Medicare & Medicaid Services (CMS) has partnered with the American College of Cardiology (ACC) to include several National Cardiovascular Data Registry (NCDR) measures as part of their Alternate Quality Measures Set. Not only can NCDR measures now do double duty, but for sites that opt in to using these alternative measures, the ACC itself will be submitting the data directly to CMS, reducing reporting burden on NCDR sites. "There was feedback from the clinician community that the measures weren't clinically specific," said Christine Perez, JD, the director of Payer & Care Delivery Policy at the ACC. Continue reading →